Skip to main content
Dana-Farber
  • person
  • dana-farber.org
  • Search
  • Featured Specialties
    • Breast Oncology
    • Gastrointestinal Oncology
    • Genitourinary Oncology
    • Gynecologic Oncology
    • Hematologic Oncology
    • Pediatric Oncology
  • Find a Physician
  • Find a Clinical Trial
  • Refer a Patient
  • Contact Us

Toni Choueiri, MD

Medical Oncology

Toni Choueiri, MD

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

View Full Profile


Related Videos

ARC-20 Study Presented by Toni Choueiri, MD. Video

ARC-20 Study Presented by Toni Choueiri, MD.

Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.

Checkmate 214 Presented by Toni Choueiri, MD. Video

Checkmate 214 Presented by Toni Choueiri, MD.

Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan Video

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101 Video

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101

Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.

Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis Video

Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis

Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.

Kidney Cancer Highlights from ESMO 2023 Video

Kidney Cancer Highlights from ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD Video

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.

ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD Video

ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD

We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.

Kidney Cancer Highlights from ESMO 2022 Video

Kidney Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022

Connect with us

Facebook_DanaFarber_Blue_icon X_DanaFarber_Blue_icon Instagram_DanaFarber_Blue_icon Youtube_DanaFarber_Blue_icon LinkedIn_DanaFarber_Blue_icon
  • About Us
  • Research
  • Medical Oncology Spotlight
  • Find a Clinical Trial
  • Find a Physician
  • Refer a Patient
  • Clinical Resources
  • Dana-Farber
Powered by BroadcastMedBROADCASTMED